Back to top

Image: Bigstock

Luminex Corporation

Read MoreHide Full Article

Luminex operates in the highly competitive life sciences industry. The industry is characterized by rapid and continuous technological innovation. The company’s gross margin contracted significantly in recent times. Further, lackluster performance by the consumable and service revenue segments is a headwind. However, strong performance by the molecular diagnostic segment instills optimism. The company is also poised well on the solid ARIES and VERIGENE platforms. Assay and royalty revenues also witnessed an upside recently. New products are likely to expand the company’s portfolio. Furthermore, solid revenue guidance for 2018 buoys optimism. Expanding operating margin is a major positive. Luminex achieved highest system placement number in its history with 361 xMAP system placements in the last-reported quarter. The company outperformed its industry in a year’s time.


In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Luminex Corporation (LMNX) - free report >>

Published in